Sutro and Merck partner in cancer/autoimmune deal; Collaboration Extended
Sutro Biopharma Inc. agreed to use its protein synthesis and conjugation platforms to discover new cancer and autoimmune disease candidates for Merck & Co. Inc.
- Large Molecule
- Synthesis Technologies, Production Processes
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.